Patents Assigned to Variagenics, Inc.
  • Patent number: 6309882
    Abstract: Compositions and methods are provided for modulating the expression of the replication protein A p70 subunit and for the treatment and diagnosis of diseases associated with replication protein A p70 subunit.
    Type: Grant
    Filed: September 10, 1999
    Date of Patent: October 30, 2001
    Assignees: ISIS Pharmaceuticals, Inc., Variagenics, Inc.
    Inventors: Brett P. Monia, James P. Basilion, Vincent P. Stanton, Jr.
  • Patent number: 6291175
    Abstract: Disclosed herein is a method for treating a patient with a neurological disease by determining a patient's BCHE allele status.
    Type: Grant
    Filed: June 16, 1999
    Date of Patent: September 18, 2001
    Assignees: Variagenics, Inc., Institut Pasteur de Lille
    Inventors: Pierre Sévigny, Keith Schappert, Heiko Wiebusch, Philippe Amouye
  • Patent number: 6200754
    Abstract: Disclosed are methods for the treatment of proliferative disorders using compounds and/or environmental conditions which result in a difference in sensitivity of targeted and non-targeted cells. Certain of the methods involve the identification and use of allele-specific inhibitors of conditionally essential genes.
    Type: Grant
    Filed: March 19, 1998
    Date of Patent: March 13, 2001
    Assignee: Variagenics, Inc.
    Inventors: David E. Housman, Fred D. Ledley, Vincent P. Stanton, Jr.
  • Patent number: 6183958
    Abstract: Disclosed are methods and reagents for detecting nucleotide mismatches (for example, due to sequence variances) in a nucleic acid sample involving the use of a nucleic acid probe derived from a hemizygous cell. Methods for determining the haplotype of a nucleic acid sample are also disclosed. Also disclosed are methods for producing the probe and kits containing the probe.
    Type: Grant
    Filed: May 6, 1998
    Date of Patent: February 6, 2001
    Assignee: Variagenics, Inc.
    Inventor: Vincent P. Stanton, Jr.
  • Patent number: 6110684
    Abstract: Disclosed herein is a method for detecting a mismatch in a duplex nucleic acid, involving: a) contacting the duplex nucleic acid with a reactive agent under conditions which permit the agent to bind but not cleave a mismatch in said duplex nucleic acid; b) detecting binding of the agent to the duplex nucleic acid as an indication of the presence of a mismatch in the duplex nucleic acid; c) contacting the duplex nucleic acid with the reactive agent under conditions which permit the agent to cleave a mismatch in the duplex nucleic acid; and d) detecting a cleavage product as an indication of the presence of a mismatch in the duplex nucleic acid.
    Type: Grant
    Filed: February 2, 1999
    Date of Patent: August 29, 2000
    Assignee: Variagenics, Inc.
    Inventors: Borries Kemper, Karin Birkenkamp-Demtroder, Stefan Golz
  • Patent number: 6054273
    Abstract: This invention is directed to a therapeutic strategy involving (1) identification of alternative alleles of genes coding for protein vital for cell viability or cell growth and the loss of one of those alleles in cancer cells due to loss of heterozygosity (LOH) and (2) the development of inhibitors with high specificity for the single remaining alternative allele of the vital gene retained by the cancer cell after LOH. The inhibitors of this invention are specific for one alternative allele of a gene that codes for a protein vital to cell viability or cell growth. The targeted gene has two alternative alleles in which the inhibitors of this invention blocks only one of the two alternative alleles, still present in the cancer cells. Exposure to the inhibitor inhibits or kills cancer cells which have undergone LOH. Protein is still capable of being expressed in the normal cells exposed to the inhibitor by the unblocked alternative allele.
    Type: Grant
    Filed: November 11, 1997
    Date of Patent: April 25, 2000
    Assignee: Variagenics Inc.
    Inventor: David E. Housman
  • Patent number: 5958692
    Abstract: Methods are disclosed for detecting one or more mutations in an isolated test nucleic acid by forming a heteroduplex with a homologous control DNA and contacting the heteroduplex with a resolvase capable of recognizing at least one single base pair mismatch within the heteroduplex. In preferred embodiments of the invention, the resolvase is bacteriophage T4 endonuclease VII.
    Type: Grant
    Filed: September 2, 1997
    Date of Patent: September 28, 1999
    Assignee: Variagenics, Inc.
    Inventors: Richard G. H. Cotton, Rima Youil, Borries W. Kemper
  • Patent number: 5851770
    Abstract: Disclosed is a method for detecting one or more mismatches between a first and a second nucleic acid, the first and second nucleic acids being capable of preferentially hybridizing.
    Type: Grant
    Filed: October 19, 1995
    Date of Patent: December 22, 1998
    Assignee: Variagenics, Inc.
    Inventors: Jeff Babon, Rima Youil, Jay Stoerker, Anne Huff, Richard G. H. Cotton
  • Patent number: 5824530
    Abstract: Disclosed are improved methods for the production and recovery of bacteriophage T4 endonclease VII.
    Type: Grant
    Filed: March 28, 1996
    Date of Patent: October 20, 1998
    Assignee: Variagenics, Inc.
    Inventors: Borries Kemper, Stefan Golz, Rainer P. Birkenbihl